Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

This study demonstrated notable time savings with daratumumab SC-based versus isatuximab IV-based regimens in patients with newly diagnosed MM who are transplant ineligible based on SC versus IV administration and less frequent daratumumab dosing.